To further verify whether CHIP combined with Gal1 had a synergetic effect on the prognosis of CRC patients, we applied clinical risk scores (TNM stage, histologic type and tumor diameter), CHIP expression, Gal1 expression and CHIP plus Gal1 expression to conduct a time-dependent ROC analysis. This evidence concerns the gene STUB1 and colorectal carcinoma.